Abstract:Alzheimer's disease (AD) is the most common neurodegenerative disorders now. Amyloid ß-protein (Aß) has been recognized as the leading cause of AD, and Aß oligomer plays an important role in the early stage of AD. Anti-Ab immunotherapy targeting on the Ab peptide has been demonstrated as one promising AD treatment. The active immunization, exploiting Ab42 as an immunogen, was initiated on AD animal model by Schenk in 1999 and then advanced to clinical trials. However, the clinical trial was haunted due to an occurrence of subacute meningoencephalitis in 6% of patients. Th1-biased responses stimulated by T cell epitope in the Ab42 and Th1-promoting adjuvant (QS-21) were ascribed to this side effect. Meanwhile, anti-Ab antibodies produced in those patients have been proved to be effective in slowering rate of cognitive decline. As an alternative, passive immunization approaches have the advantage of safety and efficacy over active immunization approaches. In this report, several strains of monoclonal antibody (MAb) against Aß1-42 oligomer or different truncation of Aß C terminal was established for AD therapeutic research. MAb specific for Aß1-42 oligomer was prepared with the hybridoma technique and purified through protein A affinity chromatography. The specificity, affinity and titers of the MAb were analyzed by ELISA, western blot and immunohistochemistry (IHC). To determine whether Antibodies treatment improves the ability of learning and memory, 8-month-old SAMP8 mice and 6-month-old APPswe/PS1DE9 mice were administered intraperitoneally and weekly with 400 mg A8 or nonspecific mouse IgG (Sigma-Aldrich) for 8 weeks. The Morris water maze (MWM) has been used for studying therapy-related changes in learning and memory in mice. The visible, hidden versions of MWM and prob trial were performed. The latency and distance to find the location that had contained the platform was measured. Data were recorded through an overhead camera linked with the computer to quantification of latency and distance. Mice were tested in a blinded manner, with group balanced for genotype and treatment. Mice were sacrificed 3 days after the final MWM manipulation for biochemical and histological assessment. Through western blot (WB) and immunohistochemistry (IHC), the soluble and insoluble Aß, phosphorylation of tau at 181/231/404 site, mTOR (mammalian target of rapamycin), LC3-I/II (microtubuler associated protein 1 light chain 3, MAP1rLC3, LC3), glial fibrillary acidic protein (GFAP), tubulin and actin were detected. Our results showed that the mice serum titer reached over 1:256,000 after immunization. Two hybridoma cell lines (BJ08 and BJNa) secreting MAb specific for the Aß1-42 oligomer was established after sub-cloning. They displayed much higher affinity to low molecular Aß1-42 oligomer, and showed the ability to bind Aß1-42 oligomer in the brain section of SAMP8 mice and APPswe/PS1DE9 mice. Using them as immunotherapy, we show that learning and memory ability was improved through intraperitoneal administration in SAMP8 mice. The mice that found the platform increased in antibody treated groups and our data showed a significant decrease in latency and distance compared with other groups (P < 0.05) (nonspecific mouse IgG, antibody solution buffer and no-treated SAMP8 or APPswe/PS1DE9 mice). Meanwhile, soluble Aß, phosphorylation of tau and LC3-II has also been inhibited after immunotherapy. In addition, the expression level of mTOR, GFAP, tubulin and actin were also detected with IHC and displayed no differences among these groups. In conclusion, the MAbs specific for Aß1-42 oligomer is developed. Therapeutic monoclonal antibodies against Aß oligomers have the efficacy in reducing soluble Aß, phosphorylation of tau and LC3-II level and ultimately ameliorated the learning and memory ability, which paves the way for further diagnostic and therapeutic research on AD.

The cell-permeable Aβ1-6A2VTAT(D) peptide reverts synaptopathy induced by Aβ1-42wt

An 18-mer Peptide Derived from Prosaposin Ameliorates the Effects of Aβ1-42 Neurotoxicity on Hippocampal Neurogenesis and Memory Deficit in Mice.

P2X receptor overexpression induced by soluble oligomers of amyloid beta peptide potentiates synaptic failure and neuronal dyshomeostasis in cellular models of Alzheimer's disease

A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro

Aβ1-42 peptide toxicity on neuronal cells: A lipidomic study

A Small TAT-TrkB Peptide Prevents BDNF Receptor Cleavage and Restores Synaptic Physiology in Alzheimer's Disease

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis.

P2‐142: Toxic Effect of the Carboxyl‐terminal Peptide of Beta‐amyloid Precursor Protein (APPC31) on Neuro2a Cells

A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology

Therapeutic Monoclonal Antibodies Against Abeta Oligomers for Treatment of Alzheimer's Disease

Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid Β Peptide Associated with Alzheimer’s Disease

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease

A Synthetic Pro-Drug Peptide Reverses Amyloid-β-Induced Toxicity in the Rat Model of Alzheimer's Disease

Transmissible long-term neuroprotective and pro-cognitive effects of 1–42 beta-amyloid with A2T icelandic mutation in an Alzheimer's disease mouse model

APP Substitutions V715F and L720P Alter PS1 Conformation and Differentially Affect Abeta and AICD Generation.

A Snake Venom Peptide and Its Derivatives Prevent Aβ42 Aggregation and Eliminate Toxic Aβ42 Aggregates In Vitro

P1-385: Protection against beta-amyloid-induced synaptic impairments via promotion of beta-amyloid oligomer aggregation by bis(heptyl)-cognitin

Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane